Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Revenues up 12% in the quarter to $6.4 billion.
November 4, 2020
By: Contract Pharma
Contract Pharma Staff
Amgen
3Q Revenues: $6.4 billion (+12%)
3Q Earnings: $2.0 billion (+3%)
YTD Revenues: $18.8 billion (+9%)
YTD Earnings: $5.6 billion (-8%)
Comments: Product sales increased 12% globally, driven by 18% volume growth across a number of our newer products, including Otezla, MVASI, KANJINTI, and Repatha, partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition. Prolia sales increased 11% to $701 million. EVENITY generated $59 million of sales in the quarter. Repatha sales increased 22% to $205 million. Aimovig sales increased 59% to $105 million. Parsabiv sales increased 17% to $183 million. Otezla generated $538 million of sales in the quarter. Enbrel sales decreased 3% to $1.3 billion. AMGEVITA increased 31% to $80 million. KYPROLIS sales decreased 2% to $260 million. XGEVA sales increased 1% to $481 million. Vectibix sales declined 2% to $193 million. Nplate sales increased 9% to $212 million. BLINCYTO sales increased 5% to $89 million. MVASI generated $231 million of sales in the quarter. KANJINTI generated $167 million of sales in the quarter. Neulasta sales decreased 22% to $555 million due to increased biosimilar competition. EPOGEN sales decreased 31% to $149 million. Aranesp sales decreased 15% to $384 million driven by lower net selling price and competition. Sensipar/Mimpara sales decreased 64% to $39 million due to generic competition.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !